<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04058613</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-TAT4-01</org_study_id>
    <nct_id>NCT04058613</nct_id>
  </id_info>
  <brief_title>Effects of Maintaining Steady Albumin Levels (TAT 4) on Survival and Liver Related Complications in Cirrhosis With Ascites</brief_title>
  <official_title>Effects of Maintaining Steady Albumin Levels by Targeted Albumin Therapy (TAT 4) on Survival and Liver Related Complications in Cirrhosis With Ascites and Low Serum Albumin Level- a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators intend to assess the utility of regular albumin infusions to maintain a
      targeted serum albumin level of 4.0 g/dl in newly detected cirrhotic patients with low
      albumin levels (&lt;2.8g/dl) with ascites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cirrhosis is characterized by progressive deterioration in liver functions. Liver's synthetic
      functions are inferred by serum albumin and INR estimation. Lower albumin level is a marker
      of severe liver disease and probability of worsening ascites, hepatorenal syndrome with
      increased risk for infections. Of the three recent RCTs on utility of long-term
      administration of albumin, two showed improvement in survival. The studies had included
      different patient populations (diuretic refractory ascites, high dose diuretics and patients
      on liver transplant waiting list) with different albumin infusion protocols and different
      end-points. These studies were done in advanced cases of cirrhosis. There is limited data on
      the utility of regular albumin infusions in early hepatic decompensation (albumin
      levels-&lt;2.8g/dl with ascites) and the effect of maintaining a targeted albumin level on
      survival or liver related side effects. Investigators are trying to address this issue by
      starting regular albumin infusions at an earlier stage of liver decompensation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 10, 2019</start_date>
  <completion_date type="Anticipated">August 8, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 8, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transplant/Transintrahepatic Portosystemic Shunt (TIPS) free survival in both groups</measure>
    <time_frame>12 months</time_frame>
    <description>1 year survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New onset refractory ascites in both the groups</measure>
    <time_frame>12 months</time_frame>
    <description>refractory ascites is defined as non response to maximum tolerated dose of diuretics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spontaneous bacterial peritonitis [SBP] in both groups</measure>
    <time_frame>12 months</time_frame>
    <description>Spontaneous bacterial peritonitis is defined as ascitic fluid absolute neutrophil count &gt; 250/ mL with or without culture positivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal impairment in both groups</measure>
    <time_frame>12 months</time_frame>
    <description>serum creatinine concentration &gt;1•5 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatorenal Syndrome in both groups</measure>
    <time_frame>12 months</time_frame>
    <description>Hepatorenal Syndrome type 1 is defined as new onset increase in serum creatinine level by 0.3 mg/dL or 50% increase from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic encephalopathy grade 3 or 4 in both groups</measure>
    <time_frame>12 months</time_frame>
    <description>HE as per West Haven criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new cases with gastrointestinal bleeding in both groups</measure>
    <time_frame>12 months</time_frame>
    <description>gastrointestinal bleeding as confirmed by endoscopic/clinical evidence of variceal bleed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement of paracentesis in both groups</measure>
    <time_frame>12 months</time_frame>
    <description>Ascitic tapping for relieve of pressure symptoms or diagnosis of SBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement of diuretics in both groups</measure>
    <time_frame>12 months</time_frame>
    <description>Frusemide or Aldactone for management of ascites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalizations per subject in both groups</measure>
    <time_frame>12 months</time_frame>
    <description>Need for any cause hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New onset breathlessness/ Hypertension within 24 hours of albumin infusion in both groups</measure>
    <time_frame>within 24 hours</time_frame>
    <description>Development of cardiac overload</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by Ascite-Q questionnaire in both groups</measure>
    <time_frame>12 months</time_frame>
    <description>semiquantitative questionnaire to be answered by the participants</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Albumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Albumin infusions will be given at a dose of 40 g twice weekly till a steady albumin level of 4.0g/dl is reached followed by 100ml of 20% albumin at least once in two weeks to maintain a steady albumin level of 4.0g/dl along with the standard medical therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALB Protein, Human</intervention_name>
    <description>Albumin infusions will be given at a dose of 40 g twice weekly till a steady albumin level of 4.0g/dl is reached followed by 100ml of 20% albumin at least once in two weeks to maintain a steady albumin level of 4.0g/dl along with the standard medical therapy</description>
    <arm_group_label>Albumin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly detected cirrhotic patients aged more than 18 years

          -  Cirrhosis deﬁned by standard clinical, analytical and/or histological criteria

          -  Serum albumin level &lt; 2.8g/dl with or without ascites

          -  Who would agree to give written informed consent

        Exclusion Criteria:

          -  Uncontrolled HTN (sys&gt;150/ dis &gt;90 mmHg) or h/o any drug therapy for HTN

          -  Prior h/o Transjugular Intrahepatic Portosystemic Shunt (TIPS)

          -  Hepatocellular Carcinoma

          -  Active alcohol abuse within 3 months

          -  Patients presenting as Acute on Chronic Liver Failure

          -  Extrahepatic organ failure

          -  Known case of chronic heart failure or respiratory failure

          -  Diagnosed Chronic Kidney Disease

          -  Patients with hydrothorax

          -  Prior liver transplant recipient

          -  Human Immunodeficiency Virus infection

          -  Use of albumin infusion in the last one month

          -  CTP&gt;12, MELD&gt;28

          -  Total Bilirubin &gt;3 g/dl

          -  Overt Hepatic Encephalopathy at Presentation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Shasthry SM, MD</last_name>
    <phone>01146300000</phone>
    <email>shasthry@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver &amp; Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Shasthry SM, MD</last_name>
      <phone>01146300000</phone>
      <email>shasthry@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 13, 2019</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2019</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Liver and Biliary Sciences, India</investigator_affiliation>
    <investigator_full_name>Shasthry SM</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

